CD73: A potential biomarker for anti-PD-1 therapy

In our recent study, we show that tumoral CD73 expression limits the efficacy of anti-PD-1 therapy, and this is rescued by concomitant A(2A) blockade. Since CD73 is known to be overexpressed in several human cancers and A(2A) antagonists have undergone clinical trials for Parkinson's Disease, t...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncoimmunology
Autores principales: Beavis, Paul A, Slaney, Clare Y, Milenkovski, Nicole, Henderson, Melissa A, Loi, Sherene, Stagg, John, Kershaw, Michael H, Darcy, Phillip K
Formato: Artigo
Lenguaje:Inglês
Publicado: Taylor & Francis 2015
Materias:
Author's View
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4589050/
https://ncbi.nlm.nih.gov/pubmed/26451321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1046675
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares